Dimensional Fund Advisors LP Sells 2,002 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Dimensional Fund Advisors LP cut its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 9.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 19,726 shares of the company’s stock after selling 2,002 shares during the quarter. Dimensional Fund Advisors LP owned 0.07% of Dianthus Therapeutics worth $510,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of DNTH. Bain Capital Life Sciences Investors LLC acquired a new position in shares of Dianthus Therapeutics during the 1st quarter valued at $89,761,000. RA Capital Management L.P. bought a new stake in Dianthus Therapeutics in the 1st quarter valued at about $69,990,000. Vanguard Group Inc. raised its stake in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after buying an additional 384,182 shares during the period. Janus Henderson Group PLC bought a new position in Dianthus Therapeutics in the first quarter worth approximately $11,251,000. Finally, Bank of New York Mellon Corp grew its stake in Dianthus Therapeutics by 860.5% in the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after acquiring an additional 72,509 shares during the period. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH opened at $27.50 on Monday. Dianthus Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $33.77. The firm has a 50-day moving average price of $27.77 and a two-hundred day moving average price of $26.12. The firm has a market cap of $807.10 million, a price-to-earnings ratio of -4.72 and a beta of 1.85.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The business had revenue of $1.86 million for the quarter, compared to the consensus estimate of $0.63 million. Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on DNTH shares. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Wedbush decreased their target price on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Oppenheimer began coverage on shares of Dianthus Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $48.00 target price on the stock. Finally, Robert W. Baird started coverage on Dianthus Therapeutics in a research note on Friday, July 26th. They set an “outperform” rating and a $58.00 price target for the company. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $45.13.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.